5-MeO-MiPT    B-DesignerDrug103179489

Moxy    O
(    O
slang    O
)    O
,    O
name    O
for    O
the    O
research    O
chemical    O
5-MeO-MIPT    B-DesignerDrug103179489

JWH-198    B-DesignerDrug103179489
—    O
(    O
1-(2-morpholin-4-ylethyl)indol-3-yl)-4-methoxynaphthalen-1-ylmethanone    O
,    O
10nM    O
at    O
CB1    O

At    O
about    O
200    O
°C    O
in    O
the    O
presence    O
of    O
soluble    O
ruthenium    O
catalysts    O
,    O
the    O
diol    O
undergoes    O
dehydrogenation    O
to    O
form    O
butyrolactone    B-DesignerDrug103179489
.    O

In    O
the    O
United    O
Kingdom    O
,    O
1,4-butanediol    O
was    O
scheduled    O
in    O
December    O
2009    O
(    O
along    O
with    O
another    O
GHB    O
precursor    O
,    O
gamma-butyrolactone    B-DesignerDrug103179489
)    O
as    O
a    O
Class    O
C    O
controlled    O
substance    O
.    O

Metabolic    O
pathway    O
of    O
1,4-butanediol    O
,    O
γ-butyrolactone    B-DesignerDrug103179489
and    O
γ-hydroxybutyric    O
acid    O
(    O
GHB    O
)    O
.    O

The    O
young    O
men    O
brought    O
them    O
the    O
cocktails    O
,    O
to    O
which    O
they    O
had    O
added    O
either    O
gamma    O
-    O
hydroxybutyric    O
acid    O
(    O
GHB    O
)    O
or    O
gamma-butyrolactone    B-DesignerDrug103179489
(    O
GBL    O
)    O
.    O

(    O
B    O
)    O
The    O
designation    O
of    O
gamma    B-DesignerDrug103179489
butyrolactone    I-DesignerDrug103179489
or    O
any    O
other    O
chemical    O
as    O
a    O
listed    O
chemical    O
pursuant    O
to    O
paragraph    O
(    O
34    O
)    O
or    O
(    O
35    O
)    O
does    O
not    O
preclude    O
a    O
finding    O
pursuant    O
to    O
subparagraph    O
(    O
A    O
)    O
of    O
this    O
paragraph    O
that    O
the    O
chemical    O
is    O
a    O
controlled    O
substance    O
analogue    O
.    O

GBL    B-DesignerDrug103179489

γ-Butyrolactone    B-DesignerDrug103179489

In    O
November    O
2005    O
,    O
Rose    O
was    O
indicted    O
for    O
distributing    O
gamma-Butyrolactone    B-DesignerDrug103179489
(    O
GBL    O
)    O
to    O
his    O
Lookouts    O
teammates    O
in    O
the    O
late    O
1990s    O
.    O

3-Fluoroamphetamine    B-DesignerDrug103179489
(    O
3-FA    O
)    O

One    O
of    O
its    O
uses    O
is    O
the    O
production    O
of    O
2,5-dimethoxyphenethylamine    O
,    O
also    O
known    O
as    O
2C    O
-    O
H.    O
2C    O
-    O
H    O
is    O
used    O
to    O
produce    O
many    O
other    O
substituted    O
phenethylamines    O
such    O
as    O
2C    O
-    O
B    O
,    O
2C-I    B-DesignerDrug103179489
and    O
2C-C    B-DesignerDrug103179489

25-C    O
-    O
NBOH    O
(    O
2C    O
-    O
C    O
-    O
NBOH    O
,    O
NBOH-2CC    O
)    O
is    O
a    O
derivative    O
of    O
the    O
phenethylamine    O
derived    O
hallucinogen    O
2C-C    B-DesignerDrug103179489
which    O
has    O
been    O
sold    O
as    O
a    O
designer    O
drug    O
.    O

While    O
this    O
nomenclature    O
has    O
not    O
caught    O
on    O
because    O
the    O
name    O
"    O
methylone    O
"    O
became    O
widely    O
used    O
before    O
the    O
conflicting    O
Methylone    O
trademark    O
was    O
noticed    O
,    O
the    O
analogous    O
names    O
for    O
related    O
chemicals    O
bk-MDEA    B-DesignerDrug103179489
and    O
bk-MBDB    B-DesignerDrug103179489
have    O
become    O
the    O
established    O
names    O
for    O
those    O
substances    O
.    O

Butylone    B-DesignerDrug103179489

2C-T-21    B-DesignerDrug103179489

With    O
the    O
exception    O
of    O
"    O
ALD-52    B-DesignerDrug103179489
"    O
,    O
all    O
of    O
the    O
substances    O
were    O
less    O
potent    O
than    O
LSD    O
.    O

ALD-52    B-DesignerDrug103179489
,    O
a    O
chemical    O
analogue    O
of    O
lysergic    O
acid    O
diethylamide    O
(    O
LSD    O
)    O

3-Methylmethcathinone    B-DesignerDrug103179489

It    O
is    O
the    O
4-dehydroxylated    O
structural    O
analog    O
of    O
diphenylprolinol    B-DesignerDrug103179489
(    O
D2PM    O
)    O
,    O
and    O
is    O
also    O
similar    O
in    O
structure    O
to    O
desoxypipradrol    B-DesignerDrug103179489
(    O
2-DPMP    O
)    O
,    O
both    O
of    O
which    O
act    O
as    O
norepinephrine    O
-    O
dopamine    O
reuptake    O
inhibitors    O
(    O
NDRIs    O
)    O
.    O

Diphenylprolinol    B-DesignerDrug103179489

AM-630    B-DesignerDrug103179489

AM-630    B-DesignerDrug103179489
(    O
6-iodopravadoline    O
)    O

#    O
PMA    B-DesignerDrug103179489
&    O
PMMA    B-DesignerDrug103179489

Modified    O
"    O
designer    O
amphetamines    O
"    O
gained    O
popularity    O
since    O
the    O
1960s    O
,    O
such    O
as    O
MDA    O
and    O
PMA    B-DesignerDrug103179489
.    O

On    O
7    O
June    O
,    O
the    O
PNP    O
Crime    O
Laboratory    O
confirmed    O
that    O
the    O
amphetamine    O
-    O
based    O
metabolites    O
"para"-Methoxyamphetamine    B-DesignerDrug103179489
and    O
methylenedioxyamphetamine    O
were    O
found    O
on    O
the    O
bodies    O
of    O
Migawa    O
and    O
Miller    O
,    O
in    O
addition    O
to    O
traces    O
of    O
methylenedioxycathinone    O
found    O
on    O
Migawa    O
.    O

After    O
consuming    O
a    O
PMA    B-DesignerDrug103179489
-    O
containing    O
ecstasy    O
tablet    O
,    O
Ickarus    O
goes    O
into    O
a    O
drug    O
-    O
induced    O
psychosis    O
,    O
eventually    O
finding    O
himself    O
naked    O
in    O
a    O
Berlin    O
hotel    O
where    O
his    O
antics    O
attract    O
the    O
attention    O
of    O
the    O
hotel    O
staff    O
.    O

In    O
a    O
recent    O
study    O
,    O
researchers    O
identified    O
thirty    O
-    O
one    O
alkaloids    O
in    O
samples    O
of    O
plant    O
foliage    O
,    O
including    O
trace    O
amounts    O
of    O
four    O
amphetamines    O
previously    O
known    O
only    O
from    O
laboratory    O
synthesis    O
:    O
amphetamine    O
,    O
methamphetamine    O
,    O
"    O
para    O
"-    O
hydroxyamphetamine    O
and    O
"para"-methoxyamphetamine    B-DesignerDrug103179489
.    O

Sulfoaildenafil    B-DesignerDrug103179489

6-MAPB    B-DesignerDrug103179489

Aildenafil    B-DesignerDrug103179489

Nichols    O
is    O
one    O
of    O
the    O
few    O
people    O
who    O
has    O
published    O
legitimate    O
research    O
on    O
the    O
chemistry    O
and    O
pharmacology    O
of    O
LSD    O
in    O
the    O
last    O
20    O
years    O
,    O
and    O
first    O
reported    O
that    O
several    O
LSD    O
analogues    O
,    O
including    O
ETH-LAD    B-DesignerDrug103179489
,    O
PRO-LAD    B-DesignerDrug103179489
,    O
and    O
AL-LAD    B-DesignerDrug103179489
,    O
were    O
more    O
potent    O
than    O
LSD    O
itself    O
.    O

2C-T-4    B-DesignerDrug103179489

Nichols    O
is    O
one    O
of    O
the    O
few    O
people    O
who    O
has    O
published    O
legitimate    O
research    O
on    O
the    O
chemistry    O
and    O
pharmacology    O
of    O
LSD    O
in    O
the    O
last    O
20    O
years    O
,    O
and    O
first    O
reported    O
that    O
several    O
LSD    O
analogues    O
,    O
including    O
ETH-LAD    B-DesignerDrug103179489
,    O
PRO-LAD    B-DesignerDrug103179489
,    O
and    O
AL-LAD    B-DesignerDrug103179489
,    O
were    O
more    O
potent    O
than    O
LSD    O
itself    O
.    O

Mebroqualone    B-DesignerDrug103179489

It    O
is    O
a    O
higher    O
homologue    O
of    O
4-Methylmethcathinone    B-DesignerDrug103179489
(    O
Mephedrone    O
)    O
and    O
4-Methylbuphedrone    O
(    O
4-MeMABP    O
)    O
,    O
and    O
the    O
p    O
-    O
Methyl    O
analogue    O
of    O
Pentedrone    B-DesignerDrug103179489
.    O

Pentedrone    B-DesignerDrug103179489

Acid    O
-    O
catalysed    O
hydrolysis    O
converts    O
HMF    O
into    O
gamma-valerolactone    B-DesignerDrug103179489
,    O
with    O
loss    O
of    O
formic    O
acid    O
.    O

γ-Valerolactone    B-DesignerDrug103179489

JWH-424    B-DesignerDrug103179489
—    O
a    O
potent    O
and    O
moderately    O
selective    O
CB2    O
agonist    O
with    O
a    O
Ki    O
of    O
5.44nM    O
at    O
CB2    O
and    O
20.9nM    O
at    O
CB1    O
.    O

It    O
is    O
the    O
4-dehydroxylated    O
structural    O
analog    O
of    O
diphenylprolinol    B-DesignerDrug103179489
(    O
D2PM    O
)    O
,    O
and    O
is    O
also    O
similar    O
in    O
structure    O
to    O
desoxypipradrol    B-DesignerDrug103179489
(    O
2-DPMP    O
)    O
,    O
both    O
of    O
which    O
act    O
as    O
norepinephrine    O
-    O
dopamine    O
reuptake    O
inhibitors    O
(    O
NDRIs    O
)    O
.    O

Desoxypipradrol    B-DesignerDrug103179489
,    O
also    O
known    O
as    O
2-diphenylmethylpiperidine    B-DesignerDrug103179489
(    O
2-DPMP    B-DesignerDrug103179489
)    O
,    O
acts    O
as    O
a    O
norepinephrine    O
-    O
dopamine    O
reuptake    O
inhibitor    O
(    O
NDRI    O
)    O
developed    O
by    O
Ciba    O
in    O
the    O
1950s    O
.    O

It    O
is    O
structurally    O
related    O
to    O
ethylone    B-DesignerDrug103179489
,    O
a    O
novel    O
designer    O
drug    O
.    O

4-Fluorofentanyl    B-DesignerDrug103179489
,    O
fluorination    O
on    O
the    O
phenyl    O
ring    O

#    O
Para-fluorofentanyl    B-DesignerDrug103179489

Parafluorofentanyl    B-DesignerDrug103179489

#    O
Rolicyclidine    B-DesignerDrug103179489

rolicyclidine    B-DesignerDrug103179489
(    O
PHP    O
,    O
PCPy    O
)    O

3-Methoxy-4-methylamphetamine    B-DesignerDrug103179489

5-MAPB    B-DesignerDrug103179489

2-Fluoroamphetamine    B-DesignerDrug103179489
(    O
2-FA    O
)    O

Dizocilpine    B-DesignerDrug103179489

In    O
animal    O
studies    O
,    O
it    O
reversed    O
dizocilpine    B-DesignerDrug103179489
-    O
induced    O
learning    O
and    O
memory    O
impairment    O
and    O
was    O
found    O
to    O
be    O
superior    O
in    O
doing    O
this    O
to    O
all    O
of    O
the    O
other    O
antipsychotics    O
examined    O
,    O
including    O
risperidone    O
,    O
olanzapine    O
,    O
quetiapine    O
,    O
clozapine    O
,    O
aripiprazole    O
,    O
and    O
haloperidol    O
.    O

3-HO    O
-    O
PCP    O
acts    O
as    O
a    O
high    O
-    O
affinity    O
uncompetitive    O
antagonist    O
of    O
the    O
NMDA    O
receptor    O
via    O
the    O
dizocilpine    B-DesignerDrug103179489
(    O
MK-801    O
)    O
site    O
(    O
Ki    O
=    O
30    O
nM    O
)    O
.    O

(    O
-)-8a    O
-    O
Phenyldecahydroquinoline    O
has    O
an    O
in    O
vivo    O
potency    O
comparable    O
to    O
that    O
of    O
(    O
+    O
)    O
MK-801    B-DesignerDrug103179489
.    O

Substances    O
with    O
dissociative    O
properties    O
include    O
ketamine    O
,    O
nitrous    O
oxide    O
,    O
alcohol    O
,    O
tiletamine    O
,    O
amphetamine    O
,    O
dextromethorphan    O
,    O
MK-801    B-DesignerDrug103179489
,    O
PCP    O
,    O
methoxetamine    O
,    O
salvia    O
,    O
muscimol    O
,    O
atropine    O
,    O
and    O
ibogaine    O
.    O

These    O
include    O
;    O
JWH-018    O
,    O
JWH-022    O
,    O
JWH-073    O
,    O
JWH-081    O
,    O
JWH-122    O
,    O
JWH-201    O
,    O
JWH-203    O
,    O
JWH-210    O
,    O
JWH-250    O
,    O
JWH-302    O
,    O
AM-694    O
,    O
AM-2201    O
,    O
RCS-4    O
,    O
RCS-4    O
butyl    O
homologue    O
,    O
2-methoxy    O
isomer    O
of    O
RCS-4    O
,    O
and    O
2-methoxy    O
isomer    O
of    O
RCS-4    O
butyl    O
homologue    O
,    O
which    O
were    O
banned    O
on    O
16    O
August    O
2011    O
,    O
JWH-019    O
,    O
JWH-200    O
and    O
AM-1220    B-DesignerDrug103179489
,    O
which    O
were    O
banned    O
on    O
14    O
October    O
2011    O
,    O
AM-2233    B-DesignerDrug103179489
,    O
banned    O
on    O
29    O
December    O
2011    O
,    O
AM-1248    B-DesignerDrug103179489
,    O
AM-2232    O
and    O
UR-144    O
,    O
banned    O
on    O
6    O
April    O
2012    O
,    O
and    O
the    O
stimulant    O
methylhexanamine    O
,    O
banned    O
on    O
9    O
April    O
2012    O
.    O

AM-1248    B-DesignerDrug103179489

Close    O
analogues    O
of    O
3-HO    O
-    O
PCP    O
include    O
PCP    O
,    O
3-MeO-PCP    B-DesignerDrug103179489
,    O
4-MeO-PCP    B-DesignerDrug103179489
,    O
3-MeO    O
-    O
PCMo    O
,    O
and    O
somewhat    O
more    O
distantly    O
ketamine    O
,    O
methoxyketamine    O
,    O
3-MeO    O
-    O
PCE    O
,    O
and    O
methoxetamine    O
.    O

methoxymethamphetamine    O
or    O
"    O
'    O
MMMA    O
)    O
,    O
which    O
is    O
most    O
closely    O
related    O
to    O
3-methoxyamphetamine    O
and    O
PMMA    B-DesignerDrug103179489
and    O
shares    O
similar    O
monoamine    O
releasing    O
effects    O
,    O
although    O
its    O
effects    O
have    O
not    O
been    O
studied    O
so    O
extensively    O
as    O
other    O
related    O
drugs    O
.    O

Methyl-MA    B-DesignerDrug103179489

#    O
PMA    B-DesignerDrug103179489
&    O
PMMA    B-DesignerDrug103179489

Pentylone    B-DesignerDrug103179489
(    O
bk    O
-    O
MBDP    O
)    O

Synthetic    B-DesignerDrug103179489
cannabis    I-DesignerDrug103179489

(    O
C9)-CP    O
47,497    O
(    O
CP    O
47,497    O
dimethylnonyl    O
homologue    O
)    O
is    O
a    O
synthetic    B-DesignerDrug103179489
cannabinoid    I-DesignerDrug103179489
,    O
a    O
CP    O
47,497    O
homologue    O
.    O

Synthetic    B-DesignerDrug103179489
cannabis    I-DesignerDrug103179489

A    O
UK    O
brand    O
name    O
for    O
a    O
synthetic    B-DesignerDrug103179489
cannabinoid    I-DesignerDrug103179489

XLR-12    O
is    O
an    O
indole    O
-    O
based    O
synthetic    B-DesignerDrug103179489
cannabinoid    I-DesignerDrug103179489
drug    O
that    O
was    O
invented    O
by    O
Abbott    O
Laboratories    O
in    O
2006    O
.    O

JWH-251    O
(    O
1-pentyl-3-(2-methylphenylacetyl)indole    O
)    O
is    O
a    O
synthetic    B-DesignerDrug103179489
cannabinoid    I-DesignerDrug103179489
from    O
the    O
phenylacetylindole    O
family    O
,    O
which    O
acts    O
as    O
a    O
cannabinoid    O
agonist    O
with    O
about    O
5x    O
selectivity    O
for    O
CB1    O
with    O
a    O
Ki    O
of    O
29nM    O
and    O
146nM    O
at    O
CB2    O
.    O

These    O
were    O
mainly    O
synthetic    B-DesignerDrug103179489
cannabis    I-DesignerDrug103179489
products    O
containing    O
ingredients    O
such    O
as    O
AB    O
-    O
FUBINACA    O
,    O
PB-22    O
(    O
QUPIC    O
)    O
,    O
5F    O
-    O
PB-22    O
,    O
SGT-24    O
(    O
CUMYL    O
-    O
PINACA    O
)    O
,    O
CP    O
55,244    O
,    O
4-F    O
-    O
AM-2201    O
,    O
4-Cl    O
-    O
AM-2201    O
,    O
5F    O
-    O
ADBICA    O
and    O
AB-005    O
.    O

Spice    B-DesignerDrug103179489
and    O
alcohol    O
related    O
violence    O
was    O
high    O
and    O
prisoners    O
lived    O
in    O
fear    O
.    O

K2    O
,    O
a    O
type    O
of    O
synthetic    B-DesignerDrug103179489
cannabis    I-DesignerDrug103179489
also    O
known    O
as    O
'    O
Spice    O
'    O

It    O
was    O
later    O
reported    O
that    O
Butler    O
had    O
consumed    O
a    O
type    O
of    O
synthetic    B-DesignerDrug103179489
cannabis    I-DesignerDrug103179489
known    O
as    O
K2    O
before    O
the    O
shootings    O
.    O

AM-1220    O
was    O
first    O
detected    O
as    O
an    O
ingredient    O
of    O
synthetic    B-DesignerDrug103179489
cannabis    I-DesignerDrug103179489
smoking    O
blends    O
in    O
2010    O
.    O

PX-3    O
(    O
also    O
known    O
as    O
APP    O
-    O
CHMINACA    O
)    O
is    O
an    O
indazole    O
-    O
based    O
synthetic    B-DesignerDrug103179489
cannabinoid    I-DesignerDrug103179489
.    O

SDB-005    O
is    O
an    O
indazole    O
-    O
based    O
synthetic    B-DesignerDrug103179489
cannabinoid    I-DesignerDrug103179489
that    O
has    O
been    O
sold    O
online    O
as    O
a    O
designer    O
drug    O
.    O

MDMB    O
-    O
CHMICA    O
(    O
also    O
incorrectly    O
known    O
as    O
MMB    O
-    O
CHMINACA    O
)    O
is    O
an    O
indole    O
-    O
based    O
synthetic    B-DesignerDrug103179489
cannabinoid    I-DesignerDrug103179489
that    O
is    O
a    O
potent    O
agonist    O
of    O
the    O
CB1    O
receptor    O
and    O
has    O
been    O
sold    O
online    O
as    O
a    O
designer    O
drug    O
.    O

9-"nor"-9β-Hydroxyhexahydrocannabinol    O
(    O
HHC    O
)    O
,    O
is    O
a    O
synthetic    B-DesignerDrug103179489
cannabinoid    I-DesignerDrug103179489
derivative    O
which    O
resulted    O
from    O
early    O
modifications    O
to    O
the    O
structure    O
of    O
THC    O
,    O
in    O
a    O
search    O
for    O
the    O
simplest    O
compound    O
that    O
could    O
still    O
fulfil    O
the    O
binding    O
requirements    O
to    O
produce    O
cannabis    O
-    O
like    O
activity    O
.    O

Unexpectedly    O
,    O
some    O
25    O
years    O
later    O
,    O
these    O
compounds    O
came    O
back    O
into    O
prominence    O
when    O
an    O
obscure    O
derivative    O
(    O
C8)-CP    O
47,497    O
was    O
found    O
to    O
have    O
been    O
sold    O
as    O
the    O
active    O
ingredient    O
in    O
the    O
"    O
herbal    O
"    O
cannabis    O
substitute    O
product    O
Spice    B-DesignerDrug103179489
,    O
which    O
ironically    O
has    O
led    O
to    O
a    O
resurgence    O
of    O
interest    O
into    O
laboratory    O
-    O
conducted    O
scientific    O
research    O
of    O
this    O
family    O
of    O
drugs    O
.    O

On    O
27    O
June    O
2017    O
,    O
the    O
Babushkinsky    O
district    O
court    O
of    O
Moscow    O
sentenced    O
Martsinkevich    O
to    O
ten    O
years    O
in    O
a    O
strict    O
regimen    O
corrective    O
labor    O
colony    O
for    O
his    O
involvement    O
in    O
attacks    O
targeting    O
synthetic    B-DesignerDrug103179489
cannabinoids    I-DesignerDrug103179489
dealers    O
.    O

His    O
lawyer    O
said    O
that    O
the    O
charges    O
were    O
related    O
to    O
Tesak    O
's    O
activities    O
against    O
smoking    B-DesignerDrug103179489
blends    I-DesignerDrug103179489
dealers    O
.    O

The    O
2014    O
-    O
15    O
list    O
of    O
NCAA    O
banned    O
drugs    O
includes    O
the    O
following    O
classes    O
:    O
stimulants    O
(    O
except    O
for    O
phenylephrine    O
and    O
pseudoephedrine    O
,    O
which    O
are    O
permitted    O
)    O
;    O
anabolic    O
agents    O
;    O
diuretics    O
and    O
other    O
masking    O
agents    O
;    O
"    O
street    O
drugs    O
"    O
(    O
the    O
NCAA    O
gives    O
as    O
examples    O
heroin    O
,    O
marijuana    O
,    O
tetrahydrocannabinol    O
(    O
THC    O
)    O
,    O
and    O
synthetic    B-DesignerDrug103179489
cannabinoids    I-DesignerDrug103179489
)    O
;    O
peptide    O
hormones    O
and    O
analogues    O
;    O
anti    O
-    O
estrogens    O
,    O
and    O
beta-2    O
agonists    O
.    O

In    O
July    O
2015    O
,    O
Bowser    O
attributed    O
the    O
spike    O
in    O
violence    O
to    O
the    O
sale    O
of    O
synthetic    B-DesignerDrug103179489
marijuana    I-DesignerDrug103179489
and    O
proposed    O
measures    O
granting    O
police    O
additional    O
authorities    O
for    O
a    O
crackdown    O
on    O
stores    O
selling    O
the    O
substance    O
.    O

Cannabinoid    O
receptor    O
1    O
agonists    O
are    O
a    O
group    O
of    O
euphoriants    O
that    O
includes    O
certain    O
plant    O
-    O
based    O
cannabinoids    O
(    O
e.g.    O
,    O
THC    O
from    O
the    O
cannabis    O
plant    O
)    O
,    O
endogenous    O
cannabinoids    O
(    O
e.g.    O
,    O
anandamide    O
)    O
,    O
and    O
synthetic    B-DesignerDrug103179489
cannabinoid    I-DesignerDrug103179489
.    O

Another    O
four    O
cannabinoid    O
compounds    O
,    O
namely    O
CB-13    O
,    O
MAM-2201    B-DesignerDrug103179489
,    O
AKB48    O
and    O
XLR-11    O
,    O
were    O
banned    O
on    O
13    O
July    O
2012    O
.    O

These    O
include    O
;    O
JWH-018    O
,    O
JWH-022    O
,    O
JWH-073    O
,    O
JWH-081    O
,    O
JWH-122    O
,    O
JWH-201    O
,    O
JWH-203    O
,    O
JWH-210    O
,    O
JWH-250    O
,    O
JWH-302    O
,    O
AM-694    O
,    O
AM-2201    O
,    O
RCS-4    O
,    O
RCS-4    O
butyl    O
homologue    O
,    O
2-methoxy    O
isomer    O
of    O
RCS-4    O
,    O
and    O
2-methoxy    O
isomer    O
of    O
RCS-4    O
butyl    O
homologue    O
,    O
which    O
were    O
banned    O
on    O
16    O
August    O
2011    O
,    O
JWH-019    O
,    O
JWH-200    O
and    O
AM-1220    B-DesignerDrug103179489
,    O
which    O
were    O
banned    O
on    O
14    O
October    O
2011    O
,    O
AM-2233    B-DesignerDrug103179489
,    O
banned    O
on    O
29    O
December    O
2011    O
,    O
AM-1248    B-DesignerDrug103179489
,    O
AM-2232    O
and    O
UR-144    O
,    O
banned    O
on    O
6    O
April    O
2012    O
,    O
and    O
the    O
stimulant    O
methylhexanamine    O
,    O
banned    O
on    O
9    O
April    O
2012    O
.    O

AM-1220    B-DesignerDrug103179489
is    O
a    O
drug    O
that    O
acts    O
as    O
a    O
potent    O
and    O
moderately    O
selective    O
agonist    O
for    O
the    O
cannabinoid    O
receptor    O
CB1    O
,    O
with    O
around    O
19x    O
selectivity    O
for    O
CB1    O
over    O
the    O
related    O
CB2    O
receptor    O
.    O

25E    O
-    O
NBOMe    O
(    O
2C    O
-    O
E    O
-    O
NBOMe    O
,    O
NBOMe-2C    O
-    O
E    O
)    O
is    O
a    O
derivative    O
of    O
the    O
phenethylamine    O
2C-E    B-DesignerDrug103179489
It    O
acts    O
in    O
a    O
similar    O
manner    O
to    O
related    O
compounds    O
such    O
as    O
25I-NBOMe    B-DesignerDrug103179489
,    O
which    O
are    O
potent    O
agonists    O
at    O
the    O
5HT2A    O
receptor    O
.    O

On    O
May    O
7    O
,    O
2011    O
,    O
in    O
the    O
United    O
States    O
,    O
two    O
young    O
adults    O
died    O
after    O
overdosing    O
on    O
Bromo    O
-    O
DragonFLY    O
,    O
which    O
they    O
thought    O
was    O
2C-E    B-DesignerDrug103179489
,    O
and    O
several    O
others    O
were    O
hospitalized    O
during    O
the    O
same    O
incident    O
.    O

Premazepam    B-DesignerDrug103179489

|    O
Ethketamine    B-DesignerDrug103179489

Polybutyrate    O
(    O
short    O
for    O
polybutyrate    O
adipate    O
terephthalate    O
,    O
or    O
PBAT    O
)    O
is    O
a    O
biodegradable    O
random    O
copolymer    O
,    O
specifically    O
a    O
copolyester    O
of    O
adipic    O
acid    O
,    O
1,4-butanediol    B-DesignerDrug103179489
and    O
dimethyl    O
terephthalate    O
.    O

PBAT    O
is    O
synthesized    O
through    O
the    O
polymers    O
butylene    O
adipate    O
(    O
polymer    O
of    O
1,4-butanediol    B-DesignerDrug103179489
and    O
adipic    O
acid    O
)    O
and    O
dimethyl    O
terephthalate    O
(    O
DMT    O
)    O
with    O
1,4-butanediol    O
.    O

The    O
polyester    O
of    O
adipic    O
acid    O
is    O
synthesized    O
using    O
1,4-butanediol    B-DesignerDrug103179489
.    O

The    O
polyester    O
of    O
DMT    O
is    O
generated    O
using    O
1,4-butanediol    B-DesignerDrug103179489
.    O

γ-Hydroxybutyraldehyde    O
,    O
also    O
referred    O
to    O
as    O
GHBAL    O
,    O
γ-hydroxybutaldehyde    O
or    O
γ-hydroxybutanal    O
,    O
is    O
a    O
chemical    O
intermediate    O
in    O
the    O
biosynthesis    O
of    O
the    O
neurotransmitter    O
γ-hydroxybutyric    O
acid    O
(    O
GHB    O
)    O
from    O
1,4-butanediol    B-DesignerDrug103179489
(    O
1,4-BD    O
)    O
.    O

1,4-Butanediol    B-DesignerDrug103179489

Phencyclamine    B-DesignerDrug103179489
or    O
PCPr    B-DesignerDrug103179489
is    O
a    O
dissociative    O
anesthetic    O
drug    O
with    O
hallucinogenic    O
and    O
stimulant    O
effects    O
.    O

2C    O
-    O
P    O
is    O
a    O
relatively    O
potent    O
and    O
long    O
acting    O
psychedelic    O
phenethylamine    O
and    O
2C    B-DesignerDrug103179489
compound    O
first    O
synthesized    O
by    O
Alexander    O
Shulgin    O
.    O

2C    O
-    O
P    O
is    O
one    O
of    O
the    O
most    O
potent    O
compounds    O
in    O
the    O
2C    B-DesignerDrug103179489
family    O
of    O
psychedelics    O
,    O
rivaled    O
only    O
by    O
2C    O
-    O
TFM    O
.    O

2Cs    B-DesignerDrug103179489
,    O
DOx    O
,    O
25-NB    O

Some    O
of    O
Shulgin    O
's    O
noteworthy    O
discoveries    O
include    O
compounds    O
of    O
the    O
2C*    B-DesignerDrug103179489
family    I-DesignerDrug103179489
(    O
such    O
as    O
2C    O
-    O
B    O
)    O
and    O
compounds    O
of    O
the    O
DOx    O
family    O
(    O
such    O
as    O
DOM    B-DesignerDrug103179489
)    O
.    O

He    O
personally    O
tested    O
hundreds    O
of    O
drugs    O
,    O
mainly    O
analogues    O
of    O
various    O
phenethylamines    O
(    O
family    O
containing    O
MDMA    O
,    O
mescaline    O
,    O
and    O
the    O
2C*    B-DesignerDrug103179489
family    I-DesignerDrug103179489
)    O
,    O
and    O
tryptamines    O
(    O
family    O
containing    O
DMT    O
and    O
psilocin    O
)    O
.    O

2C-x    B-DesignerDrug103179489

2Cs    B-DesignerDrug103179489
,    O
DOx    O
,    O
25-NB    O

2Cs    B-DesignerDrug103179489
,    O
3Cs    O
,    O
25-NB    O

3-MeO-PCP    B-DesignerDrug103179489

Close    O
analogues    O
of    O
3-HO    O
-    O
PCP    O
include    O
PCP    O
,    O
3-MeO-PCP    B-DesignerDrug103179489
,    O
4-MeO-PCP    B-DesignerDrug103179489
,    O
3-MeO    O
-    O
PCMo    O
,    O
and    O
somewhat    O
more    O
distantly    O
ketamine    O
,    O
methoxyketamine    O
,    O
3-MeO    O
-    O
PCE    O
,    O
and    O
methoxetamine    O
.    O

Benzylpiperazine    B-DesignerDrug103179489
,    O
a    O
recreational    O
drug    O

1-Benzylpiperazine    B-DesignerDrug103179489
(    O
BZP    O
)    O

mCPP    O
is    O
not    O
scheduled    O
at    O
the    O
federal    O
level    O
in    O
the    O
United    O
States    O
,    O
but    O
it    O
is    O
possible    O
that    O
it    O
could    O
be    O
considered    O
a    O
controlled    O
substance    O
analog    O
of    O
BZP    B-DesignerDrug103179489
,    O
in    O
which    O
case    O
purchase    O
,    O
sale    O
,    O
or    O
possession    O
could    O
be    O
prosecuted    O
under    O
the    O
Federal    O
Analog    O
Act    O
.    O

Jacqui    O
Dean    O
campaigned    O
for    O
the    O
banning    O
of    O
the    O
sale    O
of    O
"    O
party    O
pills    O
"    O
,    O
namely    O
Benzylpiperazine    B-DesignerDrug103179489
(    O
BZP    O
)    O
,    O
over    O
which    O
Associate    O
Health    O
Minister    O
Jim    O
Anderton    O
(    O
Progressive    O
party    O
)    O
has    O
accused    O
her    O
of    O
indulging    O
in    O
political    O
grandstanding    O
,    O
saying    O
–    O
"    O
'    O
'    O
Perhaps    O
Mrs    O
Dean    O
does    O
n't    O
subscribe    O
to    O
the    O
idea    O
that    O
any    O
Government    O
must    O
balance    O
the    O
need    O
to    O
act    O
promptly    O
with    O
its    O
responsibilities    O
to    O
act    O
fairly    O
and    O
follow    O
due    O
process    O
,    O
particularly    O
where    O
its    O
actions    O
affect    O
those    O
who    O
are    O
currently    O
acting    O
within    O
existing    O
legal    O
constraints    O
.    O
''    O
"    O
Dean    O
's    O
press    O
releases    O
refer    O
to    O
BZP    O
as    O
either    O
"    O
cattle    O
drench    O
"    O
or    O
a    O
"    O
worming    O
agent    O
"    O
.    O

Following    O
a    O
friend    O
's    O
death    O
,    O
Bowden    O
contracted    O
a    O
research    O
team    O
to    O
identify    O
safer    O
alternatives    O
to    O
illicit    O
substances    O
and    O
identified    O
benzylpiperazine    B-DesignerDrug103179489
from    O
research    O
and    O
began    O
dialogue    O
with    O
New    O
Zealand    O
's    O
Ministry    O
of    O
Health    O
Drug    O
Policy    O
Team    O
,    O
identifying    O
himself    O
as    O
a    O
community    O
member    O
with    O
a    O
potential    O
solution    O
for    O
drug    O
demand    O
reduction    O
as    O
called    O
for    O
in    O
methamphetamine    O
action    O
plan    O
.    O

benzylpiperazine    B-DesignerDrug103179489
(    O
BZP    O
)    O

Benzylpiperazine    B-DesignerDrug103179489

As    O
with    O
UK    O
based    O
head    O
shops    O
,    O
both    O
paraphernalia    O
and    O
"    O
legal    O
highs    O
"    O
are    O
available    O
from    O
these    O
stores    O
,    O
such    O
as    O
Salvia    O
Divinorum    O
and    O
BZP    B-DesignerDrug103179489
based    O
products    O
designed    O
to    O
simulate    O
illegal    O
drug    O
highs    O
such    O
as    O
those    O
experienced    O
through    O
the    O
use    O
of    O
amphetamine    O
[    O
speed    O
]    O
,    O
methamphetamine    O
,    O
and    O
psychedelics    O
[    O
psilocybin    O
]    O
.    O

His    O
lab    O
also    O
first    O
developed    O
[    O
DOI    B-DesignerDrug103179489
as    O
a    O
radioligand    O
.    O

2,5-Dimethoxy-4-iodoamphetamine    B-DesignerDrug103179489
(    O
DOI    B-DesignerDrug103179489
)    O
is    O
a    O
psychedelic    O
drug    O
and    O
a    O
substituted    O
amphetamine    O
.    O

It    O
has    O
been    O
used    O
to    O
study    O
the    O
function    O
of    O
the    O
adenosine    O
A1    O
receptor    O
in    O
animals    O
,    O
which    O
has    O
been    O
found    O
to    O
be    O
involved    O
in    O
several    O
important    O
functions    O
such    O
as    O
regulation    O
of    O
breathing    O
and    O
activity    O
in    O
various    O
regions    O
of    O
the    O
brain    O
,    O
and    O
DPCPX    O
has    O
also    O
been    O
shown    O
to    O
produce    O
behavioural    O
effects    O
such    O
as    O
increasing    O
the    O
hallucinogen    O
-    O
appropriate    O
responding    O
produced    O
by    O
the    O
5-HT2A    O
agonist    O
DOI    B-DesignerDrug103179489
,    O
and    O
the    O
dopamine    O
release    O
induced    O
by    O
MDMA    O
,    O
as    O
well    O
as    O
having    O
interactions    O
with    O
a    O
range    O
of    O
anticonvulsant    O
drugs    O
.    O

DOF    O
rather    O
resembles    O
the    O
4-unsubstituted    O
2,5-dimethoxyamphetamine    O
than    O
DOC    B-DesignerDrug103179489
,    O
DOB    B-DesignerDrug103179489
or    O
DOI    B-DesignerDrug103179489
.    O

5-Methyl-MDA    B-DesignerDrug103179489

Lysergic    B-DesignerDrug103179489
acid    I-DesignerDrug103179489
2-butyl    I-DesignerDrug103179489
amide    I-DesignerDrug103179489
(    O
2-Butyllysergamide    B-DesignerDrug103179489
,    O
LSB    B-DesignerDrug103179489
)    O
is    O
an    O
analogue    O
of    O
LSD    O
originally    O
developed    O
by    O
Richard    O
Pioch    O
at    O
Eli    O
Lilly    O
in    O
the    O
1950s    O
,    O
but    O
mostly    O
publicised    O
through    O
research    O
conducted    O
by    O
the    O
team    O
led    O
by    O
David    O
E.    O
Nichols    O
at    O
Purdue    O
University    O
.    O

Miprocin    B-DesignerDrug103179489

A    O
synthetic    O
cannabinoid    O
also    O
known    O
as    O
BTM-8    B-DesignerDrug103179489

Bromo-DragonFLY    B-DesignerDrug103179489
,    O
a    O
psychedelic    O
hallucinogen    O

Bromo-DragonFLY    B-DesignerDrug103179489
(    O
or    O
3C-Bromo-Dragonfly    B-DesignerDrug103179489
,    O
DOB-Dragonfly    B-DesignerDrug103179489
)    O
is    O
a    O
psychedelic    O
drug    O
related    O
to    O
the    O
phenethylamine    O
family    O
.    O

5-EAPB    B-DesignerDrug103179489
(    O
1-(benzofuran-5-yl)-"N"-ethylpropan-2-amine    B-DesignerDrug103179489
)    O
is    O
an    O
entactogenic    O
amphetamine    O
which    O
is    O
structurally    O
related    O
to    O
5-MAPB    B-DesignerDrug103179489
and    O
5-APB    B-DesignerDrug103179489
.    O

JWH-167    B-DesignerDrug103179489
—    O
a    O
weak    O
cannabinoid    O
agonist    O
from    O
the    O
phenylacetylindole    O
family    O
with    O
1.77x    O
selectivity    O
for    O
CB1    O
with    O
a    O
Ki    O
of    O
90nM    O
±    O
17    O
at    O
CB1    O
and    O
159nM    O
±    O
14    O
at    O
CB2    O
.    O

5-MeO-AMT    B-DesignerDrug103179489

The    O
"    O
O    O
"-    O
methylated    O
analogue    O
of    O
αMS    O
,    O
5-MeO-αMT    B-DesignerDrug103179489
,    O
also    O
readily    O
enters    O
the    O
brain    O
and    O
could    O
be    O
used    O
for    O
this    O
purpose    O
as    O
well    O
.    O

Methylone    B-DesignerDrug103179489

Bowden    O
's    O
organisation    O
Stargate    O
International    O
began    O
'    O
clinical    O
trials    O
'    O
to    O
distribute    O
EASE    O
,    O
later    O
identified    O
as    O
methylone    B-DesignerDrug103179489
,    O
after    O
receiving    O
confirmation    O
from    O
the    O
New    O
Zealand    O
Ministry    O
of    O
Health    O
that    O
the    O
product    O
was    O
legal    O
to    O
import    O
and    O
sell    O
.    O

Methylone    B-DesignerDrug103179489

Smart    O
shops    O
have    O
attempted    O
no    O
further    O
marketing    O
of    O
synthetics    O
since    O
they    O
tried    O
to    O
sell    O
methylone    B-DesignerDrug103179489
as    O
a    O
"    O
room    O
odorizer    O
"    O
but    O
were    O
ultimately    O
forced    O
to    O
pull    O
it    O
from    O
their    O
shelves    O
in    O
2004    O
,    O
though    O
it    O
can    O
still    O
be    O
obtained    O
under    O
the    O
counter    O
in    O
some    O
shops    O
.    O

DOM    B-DesignerDrug103179489
(    O
STP    O
)    O

Many    O
substituted    O
phenethylamines    O
are    O
psychoactive    O
drugs    O
which    O
belong    O
to    O
a    O
variety    O
of    O
different    O
drug    O
classes    O
,    O
including    O
central    O
nervous    O
system    O
stimulants    O
(    O
e.g.    O
,    O
amphetamine    O
)    O
,    O
hallucinogens    O
(    O
e.g.    O
,    O
2,5-dimethoxy-4-methylamphetamine    B-DesignerDrug103179489
DOM    O
)    O
,    O
entactogens    O
(    O
e.g.    O
,    O
3,4-methylenedioxyamphetamine    O
MDA    O
)    O
,    O
appetite    O
suppressants    O
(    O
e.g.    O
phentermine    O
)    O
,    O
nasal    O
decongestants    O
and    O
bronchodilators    O
(    O
e.g.    O
,    O
levomethamphetamine    O
and    O
pseudoephedrine    O
)    O
,    O
antidepressants    O
(    O
e.g.    O
bupropion    O
and    O
phenelzine    O
)    O
,    O
antiparkinson    O
agents    O
(    O
e.g.    O
,    O
selegiline    O
)    O
,    O
and    O
vasopressors    O
(    O
e.g.    O
,    O
ephedrine    O
)    O
,    O
among    O
others    O
.    O

Some    O
of    O
Shulgin    O
's    O
noteworthy    O
discoveries    O
include    O
compounds    O
of    O
the    O
2C*    B-DesignerDrug103179489
family    I-DesignerDrug103179489
(    O
such    O
as    O
2C    O
-    O
B    O
)    O
and    O
compounds    O
of    O
the    O
DOx    O
family    O
(    O
such    O
as    O
DOM    B-DesignerDrug103179489
)    O
.    O

This    O
is    O
reduced    O
to    O
the    O
2-aminoindan    O
following    O
a    O
modification    O
of    O
Nichols    O
'    O
earlier    O
method    O
from    O
a    O
paper    O
discussing    O
DOM    B-DesignerDrug103179489
analogues    O
,    O
using    O
a    O
Pd    O
/    O
C    O
catalyst    O
in    O
glacial    O
acetic    O
acid    O
with    O
catalytic    O
H2SO4    O
.    O

The    O
family    O
of    O
drugs    O
typified    O
by    O
MDMA    O
produce    O
their    O
effects    O
through    O
multiple    O
mechanisms    O
of    O
action    O
in    O
the    O
body    O
,    O
and    O
consequently    O
produce    O
three    O
distinct    O
cues    O
which    O
animals    O
can    O
be    O
trained    O
to    O
respond    O
to    O
:    O
a    O
stimulant    O
cue    O
typified    O
by    O
drugs    O
such    O
as    O
methamphetamine    O
,    O
a    O
psychedelic    O
cue    O
typified    O
by    O
drugs    O
such    O
as    O
LSD    O
and    O
DOM    B-DesignerDrug103179489
,    O
and    O
an    O
"    O
entactogen    O
-    O
like    O
"    O
cue    O
which    O
is    O
produced    O
by    O
drugs    O
such    O
as    O
MDAI    O
and    O
MBDB    O
.    O

Examples    O
of    O
substituted    O
amphetamines    O
are    O
amphetamine    O
(    O
itself    O
)    O
,    O
methamphetamine    O
,    O
ephedrine    O
,    O
cathinone    O
,    O
phentermine    O
,    O
mephentermine    O
,    O
bupropion    O
,    O
methoxyphenamine    O
,    O
selegiline    O
,    O
amfepramone    O
,    O
pyrovalerone    O
,    O
MDMA    O
(    O
ecstasy    O
)    O
,    O
and    O
DOM    B-DesignerDrug103179489
(    O
STP    O
)    O
.    O

Mephedrone    O
was    O
first    O
seized    O
in    O
France    O
in    O
May    O
2007    O
,    O
after    O
police    O
sent    O
a    O
tablet    O
they    O
assumed    O
to    O
be    O
ecstasy    O
to    O
be    O
analysed    O
,    O
with    O
the    O
discovery    O
published    O
in    O
a    O
paper    O
titled    O
"    O
Is    O
4-methylephedrone    O
,    O
an    O
"    O
Ecstasy    O
"    O
of    O
the    O
twenty    O
-    O
first    O
century    O
?    O
"    O
Mephedrone    O
was    O
reported    O
as    O
having    O
been    O
sold    O
as    O
ecstasy    O
in    O
the    O
Australian    O
city    O
of    O
Cairns    O
,    O
along    O
with    O
ethylcathinone    B-DesignerDrug103179489
,    O
in    O
2008    O
.    O

6-APB    B-DesignerDrug103179489

His    O
contributions    O
include    O
the    O
synthesis    O
and    O
reporting    O
of    O
escaline    O
,    O
LSZ    B-DesignerDrug103179489
,    O
6-APB    B-DesignerDrug103179489
,    O
2C-I-NBOMe    B-DesignerDrug103179489
and    O
other    O
NBOMe    O
variants    O
(    O
NBOMe-2C    O
-    O
B    O
,    O
NBOMe-2C    O
-    O
C    O
,    O
NBOMe-2C    O
-    O
D    O
)    O
,    O
and    O
several    O
others    O
,    O
as    O
well    O
as    O
the    O
coining    O
of    O
the    O
term    O
"    O
entactogen    O
"    O
.    O

One    O
of    O
its    O
uses    O
is    O
the    O
production    O
of    O
2,5-dimethoxyphenethylamine    O
,    O
also    O
known    O
as    O
2C    O
-    O
H.    O
2C    O
-    O
H    O
is    O
used    O
to    O
produce    O
many    O
other    O
substituted    O
phenethylamines    O
such    O
as    O
2C    O
-    O
B    O
,    O
2C-I    B-DesignerDrug103179489
and    O
2C-C    B-DesignerDrug103179489

2C-I    B-DesignerDrug103179489
is    O
a    O
psychedelic    O
phenethylamine    O
of    O
the    O
2C    B-DesignerDrug103179489
family    I-DesignerDrug103179489
.    O

2C-I    B-DesignerDrug103179489

In    O
Alexander    O
Shulgin    O
's    O
PiHKAL    O
book    O
under    O
the    O
2C-I    B-DesignerDrug103179489
entry    O
,    O
a    O
notable    O
reaction    O
is    O
observed    O
in    O
a    O
participant    O
who    O
takes    O
a    O
placebo    O
,    O
existing    O
in    O
an    O
environment    O
with    O
other    O
people    O
who    O
are    O
under    O
the    O
drug    O
's    O
influence    O
.    O

4-MTA    B-DesignerDrug103179489

a-Methyl-4-(methylthio)phenethylamine    B-DesignerDrug103179489

Flatliner    O
,    O
psychoactive    O
drug    O
4-MTA    B-DesignerDrug103179489

Other    O
drugs    O
with    O
a    O
similar    O
chemical    O
structure    O
include    O
α-pyrrolidinopropiophenone    B-DesignerDrug103179489
(    O
α-PPP    O
)    O
,    O
4'-methyl-α-pyrrolidinopropiophenone    O
(    O
M-α-PPP    O
)    O
,    O
3',4'-methylenedioxy-α-pyrrolidinopropiophenone    O
(    O
MDPPP    O
)    O
and    O
1-phenyl-2-(1-pyrrolidinyl)-1-pentanone    B-DesignerDrug103179489
(    O
α-PVP    O
)    O
.    O

α-Pyrrolidinopropiophenone    B-DesignerDrug103179489
(    O
α-PPP    B-DesignerDrug103179489
)    O
,    O
is    O
a    O
stimulant    O
drug    O
.    O

α-Pyrrolidinopropiophenone    B-DesignerDrug103179489
(    O
α-PPP    O
)    O

AM-679    B-DesignerDrug103179489
(cannabinoid)    I-DesignerDrug103179489

It    O
is    O
a    O
higher    O
homologue    O
of    O
4-Methylmethcathinone    B-DesignerDrug103179489
(    O
Mephedrone    O
)    O
and    O
4-Methylbuphedrone    O
(    O
4-MeMABP    O
)    O
,    O
and    O
the    O
p    O
-    O
Methyl    O
analogue    O
of    O
Pentedrone    B-DesignerDrug103179489
.    O

mephedrone    B-DesignerDrug103179489
(    O
4-MMC    O
)    O

As    O
a    O
result    O
,    O
many    O
of    O
them    O
have    O
become    O
controlled    O
substances    O
,    O
which    O
in    O
turn    O
has    O
resulted    O
in    O
the    O
clandestine    O
synthesis    O
of    O
a    O
vast    O
array    O
of    O
designer    O
drugs    O
for    O
the    O
purpose    O
of    O
bypassing    O
drug    O
laws    O
;    O
a    O
prime    O
example    O
of    O
such    O
is    O
the    O
mixed    O
monoamine    O
reuptake    O
inhibitor    O
and    O
releasing    O
agent    O
mephedrone    B-DesignerDrug103179489
.    O

Drugs    O
,    O
including    O
alcohol    O
,    O
anthracyclines    O
and    O
some    O
other    O
forms    O
of    O
chemotherapy    O
,    O
and    O
antipsychotics    O
,    O
e.g.    O
clozapine    O
,    O
also    O
some    O
designer    O
drugs    O
such    O
as    O
mephedrone    B-DesignerDrug103179489

It    O
started    O
to    O
be    O
sold    O
online    O
from    O
around    O
2007    O
,    O
but    O
reached    O
peak    O
popularity    O
between    O
about    O
2010    O
-    O
2012    O
,    O
after    O
bans    O
on    O
mephedrone    B-DesignerDrug103179489
came    O
into    O
effect    O
in    O
various    O
countries    O
.    O

Internet    O
-    O
sourced    O
products    O
claimed    O
to    O
be    O
MDAI    O
have    O
been    O
shown    O
variously    O
to    O
contain    O
mephedrone    B-DesignerDrug103179489
or    O
other    O
substituted    O
cathinone    O
derivatives    O
,    O
and    O
mixed    O
compositions    O
of    O
inorganic    O
substances    O
,    O
while    O
generally    O
containing    O
no    O
MDAI    O
.    O

In    O
March    O
2010    O
,    O
the    O
ACMD    O
published    O
a    O
report    O
,    O
"    O
Consideration    O
of    O
the    O
cathinones    O
"    O
,    O
which    O
recommended    O
that    O
mephedrone    B-DesignerDrug103179489
and    O
other    O
cathinones    O
should    O
be    O
made    O
illegal    O
.    O

A    O
sixth    O
member    O
,    O
Dr    O
Polly    O
Taylor    O
,    O
resigned    O
in    O
March    O
2010    O
,    O
shortly    O
before    O
the    O
decision    O
to    O
make    O
substituted    O
cathinones    O
-    O
including    O
the    O
legal    O
high    O
mephedrone    B-DesignerDrug103179489
-    O
illegal    O
.    O

An    O
inquest    O
at    O
Milton    O
Keynes    O
Coroner    O
's    O
Court    O
resulted    O
in    O
a    O
verdict    O
of    O
death    O
by    O
misadventure    O
after    O
the    O
coroner    O
heard    O
that    O
Webley    O
,    O
who    O
had    O
a    O
history    O
of    O
heart    O
disease    O
,    O
had    O
taken    O
the    O
Class    O
B    O
drug    O
mephedrone    B-DesignerDrug103179489
prior    O
to    O
the    O
heart    O
attack    O
.    O

etryptamine    B-DesignerDrug103179489
(    O
INN    O
)    O

#    O
Etryptamine    B-DesignerDrug103179489

"    O
United    O
States    O
v.    O
Forbes    O
"    O
,    O
806    O
F.    O
Supp    O
.    O
232    O
(    O
D.    O
Colo.    O
1992    O
)    O
,    O
a    O
Colorado    O
district    O
court    O
case    O
,    O
considered    O
the    O
question    O
of    O
whether    O
the    O
drug    O
alphaethyltryptamine    B-DesignerDrug103179489
(    O
AET    O
)    O
was    O
a    O
controlled    O
substance    O
analogue    O
in    O
the    O
USA    O
.    O

etryptamine    B-DesignerDrug103179489
(    O
αET    O
)    O

It    O
is    O
the    O
beta    O
-    O
hydroxy    O
analog    O
of    O
2C-D    B-DesignerDrug103179489
BOHD    O
was    O
first    O
synthesized    O
by    O
Alexander    O
Shulgin    O
.    O

DESOXY    O
is    O
also    O
an    O
isomer    O
of    O
2C-D    B-DesignerDrug103179489
which    O
would    O
cause    O
it    O
to    O
fall    O
within    O
the    O
definitions    O
outlined    O
by    O
the    O
Federal    O
Analogue    O
Act    O

It    O
is    O
closely    O
related    O
on    O
a    O
structural    O
level    O
to    O
a    O
number    O
of    O
other    O
stimulants    O
,    O
such    O
as    O
MDPV    B-DesignerDrug103179489
and    O
prolintane    O
(    O
Promotil    O
,    O
Katovit    O
)    O
.    O

Methylenedioxypyrovalerone    B-DesignerDrug103179489
(    O
MDPV    O
)    O

Analogues    O
of    O
α-PPP    O
such    O
as    O
pyrovalerone    O
and    O
MDPV    B-DesignerDrug103179489
have    O
been    O
more    O
widely    O
used    O
and    O
are    O
presumed    O
to    O
be    O
more    O
potent    O
and    O
addictive    O
than    O
α-PPP    O
itself    O
.    O

MDPV    B-DesignerDrug103179489
:    O
Medium    O
-    O
duty    O
passenger    O
vehicle    O

Excited    O
delirium    O
occurs    O
most    O
commonly    O
in    O
males    O
with    O
a    O
history    O
of    O
serious    O
mental    O
illness    O
or    O
acute    O
or    O
chronic    O
drug    O
abuse    O
,    O
particularly    O
stimulant    O
drugs    O
such    O
as    O
cocaine    O
and    O
MDPV    B-DesignerDrug103179489
.    O

People    O
with    O
excited    O
delirium    O
commonly    O
have    O
acute    O
drug    O
intoxication    O
,    O
generally    O
psychostimulants    O
such    O
as    O
cocaine    O
,    O
PCP    O
,    O
methylenedioxypyrovalerone    B-DesignerDrug103179489
(    O
MDPV    O
)    O
,    O
and    O
methamphetamine    O
.    O

MDPV    B-DesignerDrug103179489
,    O
a    O
chemical    O

Dipropyltryptamine    B-DesignerDrug103179489
,    O
a    O
psychedelic    O
tryptamine    O

Dipropyltryptamine    O
("'DPT    B-DesignerDrug103179489
,    O
also    O
known    O
as    O
"    O
The    O
Light    O
"    O
)    O
is    O
a    O
psychedelic    O
drug    O
belonging    O
to    O
the    O
tryptamine    O
family    O
,    O
first    O
reported    O
in    O
1973    O
.    O

para    O
"-    O
Methoxyethylamphetamine    O
("'PMEA    B-DesignerDrug103179489
)    O
,    O
is    O
a    O
stimulant    O
drug    O
related    O
to    O
PMA    B-DesignerDrug103179489
.    O

The    O
commander    O
's    O
capacity    O
for    O
analysis    O
and    O
critical    O
assessment    O
of    O
the    O
situation    O
were    O
possibly    O
limited    O
as    O
a    O
result    O
of    O
the    O
effects    O
of    O
the    O
benzodiazepine    O
drug    O
phenazepam    B-DesignerDrug103179489
found    O
in    O
his    O
muscle    O
tissue    O
.    O

Pack    O
of    O
Phenazepam    B-DesignerDrug103179489
,    O
found    O
in    O
Moldovan    O
pilot    O
Pavel    O
Gruzin    O
's    O
crew    O
bag    O
..    O

meta    O
"-    O
Chlorophenylpiperazine    O
("'mCPP    B-DesignerDrug103179489
)    O
is    O
a    O
psychoactive    O
drug    O
of    O
the    O
phenylpiperazine    O
class    O
.    O

Trazodone    O
,    O
both    O
itself    O
and    O
via    O
its    O
major    O
active    O
metabolite    O
"meta"-chlorophenylpiperazine    B-DesignerDrug103179489
(    O
mCPP    O
)    O
,    O
also    O
binds    O
to    O
a    O
variety    O
of    O
other    O
receptors    O
.    O

The    O
drug    O
is    O
extensively    O
metabolized    O
,    O
with    O
three    O
or    O
four    O
major    O
metabolites    O
having    O
been    O
identified    O
in    O
the    O
human    O
body    O
,    O
particularly    O
mCPP    B-DesignerDrug103179489
,    O
which    O
may    O
contribute    O
to    O
the    O
side    O
effect    O
profile    O
of    O
trazodone    O
and    O
which    O
probably    O
accounts    O
for    O
trazodone    O
's    O
serotonergic    O
effects    O
.    O

Lysergic    B-DesignerDrug103179489
acid    I-DesignerDrug103179489
2,4-dimethylazetidide    I-DesignerDrug103179489

2C-T-7    B-DesignerDrug103179489
,    O
a    O
hallucinogenic    O
phenethylamine    O

In    O
the    O
United    O
States    O
,    O
2C    O
-    O
T-19    O
is    O
not    O
illegal    O
,    O
but    O
possession    O
and    O
sales    O
of    O
2C    O
-    O
T-19    O
could    O
be    O
prosecuted    O
under    O
the    O
Federal    O
Analog    O
Act    O
because    O
of    O
its    O
structural    O
similarities    O
to    O
2C-T-7    B-DesignerDrug103179489
.    O

2C-T-7    B-DesignerDrug103179489

JWH-193    B-DesignerDrug103179489

JWH-193    B-DesignerDrug103179489

Methylmethaqualone    B-DesignerDrug103179489

Specifically    O
these    O
include    O
5-APB    B-DesignerDrug103179489
,    O
6-APB    B-DesignerDrug103179489
,    O
5-APDB    O
,    O
6-APDB    O
and    O
their    O
N    O
-    O
methyl    O
derivatives    O
5-MAPB    B-DesignerDrug103179489
,    O
6-MAPB    B-DesignerDrug103179489
,    O
5-MAPDB    B-DesignerDrug103179489
and    O
6-MAPDB    B-DesignerDrug103179489
,    O
as    O
well    O
as    O
5-IT    O
and    O
its    O
isomer    O
6-IT    O
,    O
plus    O
NBOMe-2C    O
-    O
C    O
,    O
NBOMe-2C    O
-    O
B    O
,    O
NBOMe-2C-I    B-DesignerDrug103179489
and    O
NBOMe-2C    O
-    O
D.    O

4-Fluorophenylpiperazine    B-DesignerDrug103179489
(    O
pFPP    O
)    O

2-Fluoroamphetamine    O
differs    O
from    O
3-    B-DesignerDrug103179489
and    O
4-fluoroamphetamine    B-DesignerDrug103179489
in    O
the    O
position    O
of    O
the    O
fluorine    O
atom    O
on    O
the    O
aromatic    O
ring    O
,    O
making    O
them    O
positional    O
isomers    O
of    O
one    O
another    O
.    O

4-Fluoroamphetamine    B-DesignerDrug103179489
(    O
4-FA    O
)    O

Nichols    O
is    O
one    O
of    O
the    O
few    O
people    O
who    O
has    O
published    O
legitimate    O
research    O
on    O
the    O
chemistry    O
and    O
pharmacology    O
of    O
LSD    O
in    O
the    O
last    O
20    O
years    O
,    O
and    O
first    O
reported    O
that    O
several    O
LSD    O
analogues    O
,    O
including    O
ETH-LAD    B-DesignerDrug103179489
,    O
PRO-LAD    B-DesignerDrug103179489
,    O
and    O
AL-LAD    B-DesignerDrug103179489
,    O
were    O
more    O
potent    O
than    O
LSD    O
itself    O
.    O

A    O
recent    O
study    O
has    O
shown    O
that    O
mixtures    O
of    O
BZP    O
with    O
other    O
piperazine    O
drugs    O
such    O
as    O
TFMPP    B-DesignerDrug103179489
share    O
certain    O
pharmacodynamic    O
traits    O
with    O
MDMA    O
.    O

3-Trifluoromethylphenylpiperazine    B-DesignerDrug103179489
(    O
TFMPP    O
)    O

TFMPP    B-DesignerDrug103179489

It    O
is    O
closely    O
related    O
to    O
several    O
other    O
piperazines    O
,    O
including    O
eltoprazine    O
and    O
batoprazine    O
,    O
and    O
TFMPP    B-DesignerDrug103179489
,    O
as    O
well    O
as    O
more    O
distantly    O
to    O
the    O
azapirones    O
such    O
as    O
buspirone    O
.    O

Flephedrone    B-DesignerDrug103179489

Flephedrone    B-DesignerDrug103179489
,    O
also    O
known    O
as    O
4-fluoromethcathinone    B-DesignerDrug103179489
(    O
4-FMC    B-DesignerDrug103179489
)    O
,    O
is    O
a    O
stimulant    O
drug    O
of    O
the    O
cathinone    O
chemical    O
class    O
that    O
has    O
been    O
sold    O
online    O
as    O
a    O
designer    O
drug    O
starting    O
in    O
2008    O
.    O

Naphyrone    B-DesignerDrug103179489

Naphyrone    B-DesignerDrug103179489
(    O
O-2482    O
)    O

4-Methoxyphenylpiperazine    B-DesignerDrug103179489
(    O
MeOPP    O
)    O

2C-B-FLY    B-DesignerDrug103179489

It    O
is    O
a    O
analogue    O
of    O
α-PVP    B-DesignerDrug103179489
where    O
the    O
phenyl    O
ring    O
has    O
been    O
replaced    O
by    O
thiophene    O
.    O

α-Pyrrolidinopentiophenone    B-DesignerDrug103179489

a-PVP    B-DesignerDrug103179489
,    O
a    O
chemical    O

DIPT    B-DesignerDrug103179489

diisopropyltryptamine    B-DesignerDrug103179489
(DiPT)    I-DesignerDrug103179489

Diisopropyltryptamine    B-DesignerDrug103179489
,    O
a    O
psychedelic    O
hallucinogenic    O
drug    O

Acetildenafil    B-DesignerDrug103179489
and    O
other    O
synthetic    O
structural    O
analogs    O
of    O
sildenafil    O
which    O
are    O
PDE5    O
inhibitors    O
have    O
been    O
found    O
as    O
adulterants    O
in    O
a    O
number    O
of    O
"    O
herbal    O
"    O
aphrodisiac    O
products    O
sold    O
over    O
-    O
the    O
-    O
counter    O
.    O

Specifically    O
these    O
include    O
5-APB    B-DesignerDrug103179489
,    O
6-APB    B-DesignerDrug103179489
,    O
5-APDB    O
,    O
6-APDB    O
and    O
their    O
N    O
-    O
methyl    O
derivatives    O
5-MAPB    B-DesignerDrug103179489
,    O
6-MAPB    B-DesignerDrug103179489
,    O
5-MAPDB    B-DesignerDrug103179489
and    O
6-MAPDB    B-DesignerDrug103179489
,    O
as    O
well    O
as    O
5-IT    O
and    O
its    O
isomer    O
6-IT    O
,    O
plus    O
NBOMe-2C    O
-    O
C    O
,    O
NBOMe-2C    O
-    O
B    O
,    O
NBOMe-2C-I    B-DesignerDrug103179489
and    O
NBOMe-2C    O
-    O
D.    O

5-APB    B-DesignerDrug103179489

βk-2C-B    B-DesignerDrug103179489
(    O
beta-keto    B-DesignerDrug103179489
2C-B    I-DesignerDrug103179489
,    O
bk-2C-B    B-DesignerDrug103179489
)    O
is    O
a    O
psychedelic    O
drug    O
which    O
is    O
structurally    O
related    O
to    O
2C    O
-    O
B    O
and    O
BOB    O
and    O
has    O
been    O
sold    O
online    O
as    O
a    O
designer    O
drug    O
.    O

25I-NBOMe    B-DesignerDrug103179489

25E    O
-    O
NBOMe    O
(    O
2C    O
-    O
E    O
-    O
NBOMe    O
,    O
NBOMe-2C    O
-    O
E    O
)    O
is    O
a    O
derivative    O
of    O
the    O
phenethylamine    O
2C-E    B-DesignerDrug103179489
It    O
acts    O
in    O
a    O
similar    O
manner    O
to    O
related    O
compounds    O
such    O
as    O
25I-NBOMe    B-DesignerDrug103179489
,    O
which    O
are    O
potent    O
agonists    O
at    O
the    O
5HT2A    O
receptor    O
.    O

25I-NBOMe    B-DesignerDrug103179489
(    O
NBOMe-2C    O
-    O
I    O
)    O

25P    O
-    O
NBOMe    O
(    O
2C    O
-    O
P    O
-    O
NBOMe    O
,    O
NBOMe-2C    O
-    O
P    O
)    O
is    O
a    O
derivative    O
of    O
the    O
phenethylamine    O
2C    O
-    O
P.    O
It    O
acts    O
in    O
a    O
similar    O
manner    O
to    O
related    O
compounds    O
such    O
as    O
25I-NBOMe    B-DesignerDrug103179489
,    O
which    O
are    O
potent    O
agonists    O
at    O
the    O
5HT2A    O
receptor    O
.    O

25I-NBOMe    B-DesignerDrug103179489
(    O
NBOMe-2C    O
-    O
I    O
)    O

Specifically    O
these    O
include    O
5-APB    B-DesignerDrug103179489
,    O
6-APB    B-DesignerDrug103179489
,    O
5-APDB    O
,    O
6-APDB    O
and    O
their    O
N    O
-    O
methyl    O
derivatives    O
5-MAPB    B-DesignerDrug103179489
,    O
6-MAPB    B-DesignerDrug103179489
,    O
5-MAPDB    B-DesignerDrug103179489
and    O
6-MAPDB    B-DesignerDrug103179489
,    O
as    O
well    O
as    O
5-IT    O
and    O
its    O
isomer    O
6-IT    O
,    O
plus    O
NBOMe-2C    O
-    O
C    O
,    O
NBOMe-2C    O
-    O
B    O
,    O
NBOMe-2C-I    B-DesignerDrug103179489
and    O
NBOMe-2C    O
-    O
D.    O

JWH-149    B-DesignerDrug103179489
is    O
a    O
synthetic    O
cannabimimetic    O
that    O
was    O
discovered    O
by    O
John    O
W.    O
Huffman    O
.    O

Like    O
AB-001    B-DesignerDrug103179489
,    O
APICA    O
is    O
a    O
CB1    O
and    O
CB2    O
agonist    O
possessing    O
moderate    O
cannabimimetic    O
potency    O
in    O
rats    O
.    O

SDB-006    O
—    O
is    O
a    O
benzylic    O
analogue    O
of    O
APICA    O
,    O
and    O
was    O
discovered    O
during    O
research    O
related    O
to    O
AB-001    B-DesignerDrug103179489
and    O
APICA    O
.    O

#    O
Eticyclidine    B-DesignerDrug103179489

eticyclidine    B-DesignerDrug103179489
(    O
PCE    O
)    O

Following    O
the    O
ban    O
,    O
other    O
phenethylamines    O
were    O
sold    O
in    O
place    O
of    O
2C    O
-    O
B    O
until    O
the    O
Netherlands    O
became    O
the    O
first    O
country    O
in    O
the    O
world    O
to    O
ban    O
2C-I    B-DesignerDrug103179489
,    O
2C-T-2    B-DesignerDrug103179489
and    O
2C-T-7    B-DesignerDrug103179489
alongside    O
2C    O
-    O
B.    O

In    O
Australia    O
,    O
2C-T-2    B-DesignerDrug103179489
and    O
2C    O
-    O
T-7    O
are    O
covered    O
by    O
the    O
country    O
's    O
analogue    O
drug    O
laws    O
.    O

2C-T-2    B-DesignerDrug103179489

DOI    O
is    O
not    O
scheduled    O
in    O
the    O
United    O
States    O
,    O
but    O
it    O
is    O
likely    O
that    O
DOI    O
would    O
be    O
considered    O
an    O
analog    O
(    O
of    O
DOB    B-DesignerDrug103179489
)    O
,    O
in    O
which    O
case    O
,    O
sales    O
or    O
possession    O
could    O
be    O
prosecuted    O
under    O
the    O
Federal    O
Analogue    O
Act    O
.    O

DOB    B-DesignerDrug103179489

DOB    B-DesignerDrug103179489

DOF    O
rather    O
resembles    O
the    O
4-unsubstituted    O
2,5-dimethoxyamphetamine    O
than    O
DOC    B-DesignerDrug103179489
,    O
DOB    B-DesignerDrug103179489
or    O
DOI    B-DesignerDrug103179489
.    O

Indanylaminopropane    B-DesignerDrug103179489

2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine    B-DesignerDrug103179489

2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine    B-DesignerDrug103179489

etizolam    B-DesignerDrug103179489
(    O
INN    O
)    O

Indus    O
Pharmaceuticals    O
is    O
an    O
Indian    O
pharmaceutical    O
company    O
,    O
best    O
known    O
for    O
being    O
the    O
primary    O
producer    O
of    O
the    O
Thienodiazepine    O
drug    O
Etizolam    B-DesignerDrug103179489
,    O
which    O
is    O
produced    O
and    O
marketed    O
under    O
the    O
brand    O
name    O
Etilaam    O
.    O

DOF    O
rather    O
resembles    O
the    O
4-unsubstituted    O
2,5-dimethoxyamphetamine    O
than    O
DOC    B-DesignerDrug103179489
,    O
DOB    B-DesignerDrug103179489
or    O
DOI    B-DesignerDrug103179489
.    O

These    O
include    O
;    O
JWH-018    O
,    O
JWH-022    O
,    O
JWH-073    O
,    O
JWH-081    O
,    O
JWH-122    O
,    O
JWH-201    O
,    O
JWH-203    O
,    O
JWH-210    O
,    O
JWH-250    O
,    O
JWH-302    O
,    O
AM-694    O
,    O
AM-2201    O
,    O
RCS-4    O
,    O
RCS-4    O
butyl    O
homologue    O
,    O
2-methoxy    O
isomer    O
of    O
RCS-4    O
,    O
and    O
2-methoxy    O
isomer    O
of    O
RCS-4    O
butyl    O
homologue    O
,    O
which    O
were    O
banned    O
on    O
16    O
August    O
2011    O
,    O
JWH-019    O
,    O
JWH-200    O
and    O
AM-1220    B-DesignerDrug103179489
,    O
which    O
were    O
banned    O
on    O
14    O
October    O
2011    O
,    O
AM-2233    B-DesignerDrug103179489
,    O
banned    O
on    O
29    O
December    O
2011    O
,    O
AM-1248    B-DesignerDrug103179489
,    O
AM-2232    O
and    O
UR-144    O
,    O
banned    O
on    O
6    O
April    O
2012    O
,    O
and    O
the    O
stimulant    O
methylhexanamine    O
,    O
banned    O
on    O
9    O
April    O
2012    O
.    O

AM-2233    B-DesignerDrug103179489

5-MeO-DIPT    B-DesignerDrug103179489

5-methoxy    O
-    O
diisopropyltryptamine    O
(5-MeO-DiPT    B-DesignerDrug103179489
)    O
,    O
sometimes    O
called    O
"Foxy"    B-DesignerDrug103179489
,    O
is    O
a    O
psychedelic    O
tryptamine    O
.    O

DPT    O
is    O
not    O
scheduled    O
at    O
the    O
federal    O
level    O
in    O
the    O
United    O
States    O
,    O
but    O
it    O
could    O
be    O
considered    O
an    O
analog    O
of    O
5-MeO-DiPT    B-DesignerDrug103179489
,    O
DMT    O
,    O
or    O
DET    O
,    O
in    O
which    O
case    O
purchase    O
,    O
sale    O
,    O
or    O
possession    O
could    O
be    O
prosecuted    O
under    O
the    O
Federal    O
Analog    O
Act    O
.    O

Tenocyclidine    B-DesignerDrug103179489

#    O
Tenocyclidine    B-DesignerDrug103179489

tenocyclidine    B-DesignerDrug103179489
(    O
TCP    O
)    O


